Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0828520070110020074
Journal of the Korean Geriatrics Society
2007 Volume.11 No. 2 p.74 ~ p.82
Effect of Galantamine on Caregiver Time and Activities of Daily Living in Mild to Moderate Alzheimer¡¯s Disease: A 1-Year Prospective Study
Suh Guk-Hee

Jung Hee-Yeon
Lee Chang-Uk
Lee Sang-Kyu
Lee Nam-Jin
Kim Jae-Hyun
Kee Baik-Seok
Ko Dae-Gwan
Kim Young-Hoon
Hong In-Ja
Choi Sung-Ku
Micheal Gold
Abstract
Objective: This study aims to investigate the effect of galantamine on caregiver time and activities of daily living(ADLs) in patients with mild to moderate Alzheimer¡¯s disease(AD) in a Korean population.

Design: Quasi-experimental study: A rndomized, double-blind, parallel-group clinical trial and a naturalistic longitudinal community study

Method: For this 1-year prospective study, 138 patients residing in the community were recruited(baseline MMSE score of. 10-22). The two groups were composed of 72 patients treated with galantamine and 66 patients selected as the control group from an untreated community cohort of AD patients. The primary efficacy outcome was the caregiver time and the secondary efficacy measure was the Korean version of the Disability Assessment for Dementia(DAD-K) scale.

Results: The results of a mixed model analyses demonstrated reduced caregiver time and improved ADLs in galantamine group relative to baseline and compared with the community control group in this 1-year prospective study. Significant improvement in galantamine group observed in the DAD scores demonstrated beneficial effects of galantamine on delaying functional deterioration in patients with mild to moderate AD. Difference in caregiver time between two groups was equivalent to additional 9.5 working days per month or 113 working days per year.

Conclusions: Treatment with Galantamine is associated with a significantly slower decline in basic and instrumental ADLs in patients with mild to moderated AD. These benefits on functional capacity in patients with AD treated with galantamine were associated with less caregiver time, lower caregiver burden and higher economic benefits.
KEYWORD
Galantamine, Caregiver time, Alzheimer¡¯s disease, Clinical trial, Prospective study, Function, Benefit, economy, Burden
FullTexts / Linksout information
  
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø